Precision Nanomedicine-based Diagnostics And Therapeutics For Refractory Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$7,329,484.00
Summary
The vast majority of cancer patients die of their disease due to the emergence of drug resistant cancer cells or metastatic disease that is diagnosed at late stages. Our program aims to develop new types of therapy to specifically target aggressive cancers. To detect cancer early and evaluate the effectiveness of cancer therapy, we will develop sensitive diagnostic tools and devices. This research has application to both childhood and adult cancers.
Risk Factors, Early Diagnosis, And Effective Interventions For Neurocognitive Disorders
Funder
National Health and Medical Research Council
Funding Amount
$7,013,299.00
Summary
This program will focus on early detection of dementia, identification of novel risk factors, and development of new treatments, to help the burden of dementia in our community. It will build on three longitudinal studies – Memory and Ageing Study, Older Australian Twins Study and Sydney Centenarian Study, and three international consortia – COSMIC, STROKOG and ICC-Dementia, that the investigators have developed to achieve these aims. A prevention trial for post-stroke dementia is planned
Frontotemporal Dementia And Motor Neurodegenerative Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$17,069,580.00
Summary
Frontotemporal degeneration of the brain is a leading cause of morbidity due to a pathologically heterogeneous, rapidly-progressive group of disorders with behavioural, language and motor deficits. Our internationally recognized team will continue to develop the necessary tools and therapies to effectively diagnose, manage and treat these disorders. Our focus in this program is to understand the unusual genetics underpinning these disorders, and to fast track any potential treatments.